• Will Scaled-Back Net Neutrality Shrink Your Online Audience?

    Guest Commentary by on April 10th, 2017

    Net neutrality is making headlines again—and that could affect your marketing practices. So what exactly is net neutrality, what’s likely in store for it, and what does this mean for you? According to the FCC, an Open Internet—or Net Neutrality—simply means consumers can go where they want, when they want. And in late February 2015, […]

  • Second Thoughts on Point-of-Care Advertising

    Guest Commentary by on March 17th, 2017

    A client recently asked me whether the groundswell of claims that POC advertising is highly effective might be too good to be true. I began the assignment by considering a “finding” from a leading media company and a “claim” from a leading POC vendor: 1. Kantor Media finds that “…point-of-care advertising is now the second […]

  • From Obamacare to Trumpcare: America Readies for Change

    Guest Commentary by on February 24th, 2017

    The Affordable Care Act (ACA) has been a magnet for heated Beltway conversation since inception. Health cost, benefits, and perceptions fueled debate on the future of the nation’s nascent “insurance for everyone” program throughout the elections. Yet, the surge in ACA enrollment during the Obama Administration’s last weeks signaled that for the uninsured, “getting on […]

  • How to Bring Mental Health Reform Over the Finish Line

    Guest Commentary by on January 18th, 2017

    With so many industries waiting for Team Trump to unveil a roadmap, it may seem arbitrary to zoom in on mental health. It’s not. Our nation’s deficiencies in this area add up to a crisis like no other. Before the presidential election, we were on the brink of addressing key aspects of this crisis through […]

  • Obamacare Coverage is Sick and Getting Worse

    Guest Commentary by on December 21st, 2016

    The Affordable Care Act’s (ACA) 4th open enrollment began November 1. The occasion was accompanied by news that premiums are up sharply for 2017. The benchmark silver plan increased by nearly one-quarter (22%), on average. This is a considerable sum if, for example, your monthly premium rose from $400 to $500. However, the increase is […]

  • Your Job is Hard. And Maybe—Just Maybe—Your Agencies Made it Harder

    Guest Commentary by on November 23rd, 2016

    In case you haven’t thought about it, the average length of a client-agency relationship is less than four years. The average tenure of a Chief Marketing Officer is even shorter—less than two years. If that also gets you thinking about how stressful life is for brand marketers on the front line, one of the major […]

  • 4 Ways Pharmaceutical Reps Can Unlock the Power of EHRs

    Guest Commentary by on October 31st, 2016

    Electronic health records (EHRs), now used by 83% of office-based physicians1 present both opportunities and challenges for pharmaceutical manufacturers. These issues primarily exist because there are 700 different EHRs enabled for ePrescribing2 and because of their software, industry standards and regulations are constantly evolving. It is difficult for pharmaceutical reps to manage this dynamic environment […]

  • In Crisis: Opioids, Pain, and Patients

    Guest Commentary by on September 15th, 2016

    While virtually every one of us knows of someone affected, the latest data on the opioid crisis from the CDC are startling. More than two million Americans are addicted to painkillers and nearly a half million people have died from overdoses of prescription narcotics since the year 2000. The addiction and deaths happened in all […]

  • This Year, Ignore Cost at Your Own Risk

    Guest Commentary by on August 23rd, 2016

    It’s August. For many pharmaceutical marketers, that means brand-planning time: All-day meetings, 150-slide presentation decks, SWOT workshops in stuffy conference rooms—you know the drill. No matter what brand you support, I’m guessing there’s a bullet in the “Threats” section of your SWOT this year that reads something like this: Frustration over rising cost of drugs […]

  • Healthcare, Marketing—And Privacy Issues

    Guest Commentary by on June 20th, 2016

    The future of healthcare is based on individuals’ sharing information at the click of a button, which offers efficiency and increased consumer engagement. Under (HIPAA)1, consumers have a right to access and use their health information when, where, and how they want to, including sending it to third-party apps.2 At the same time, HIPAA also […]

  • Pharma Takes a Big Step Forward in Mobile—Finally

    Guest Commentary by on May 25th, 2016

    If these first few months have been any indication, 2016 is poised to be a big year for pharma marketers in mobile advertising. To date, pharma has virtually missed out on the mobile revolution and is years behind other less-regulated industries—but its mobile push is finally gaining significant momentum. The impetus for this is two-fold: […]

  • When Angels Invest

    Guest Commentary by on April 15th, 2016

    As an investor and advocate for healthcare innovation, the last 5 to 10 years have been extremely exciting, especially with respect to the healthcare, technology, and life sciences sectors. In fact, several may argue that this time frame has nurtured some of the most promising early-stage startup companies, and has thus afforded some of the […]

  • A Win-Win for Pharma

    Among the latest organizational attempts to provide Medicare patients with access to high-quality, cost-effective care are Medicare Accountable Care Organizations (M-ACOs). The novelty of M-ACOs: Shared savings meant to incentivize quality performance and include providers in governmental savings. One issue: M-ACOs are not responsible for Medicare Part-D treatments but are responsible for negative outcomes costs […]

Back to top